AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 1.36 |
Market Cap | 220.97M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -1.09 |
PE Ratio (ttm) | -3.1 |
Forward PE | n/a |
Analyst | Buy |
Ask | 5.4 |
Volume | 24,675 |
Avg. Volume (20D) | 27,662 |
Open | 3.45 |
Previous Close | 3.43 |
Day's Range | 3.31 - 3.45 |
52-Week Range | 2.70 - 7.37 |
Beta | undefined |
About SOPH
SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Su...
Analyst Forecast
According to 3 analyst ratings, the average rating for SOPH stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 107.10% from the latest price.
Next Earnings Release
Analysts project revenue of $18.10M, reflecting a 6.17% YoY growth and earnings per share of -0.23, making a -37.84% decrease YoY.